Comparative Pharmacology
Head-to-head clinical analysis: LUMIZYME versus STRENSIQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUMIZYME versus STRENSIQ.
LUMIZYME vs STRENSIQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alglucosidase alfa is a recombinant form of human acid alpha-glucosidase (GAA), which hydrolyzes lysosomal glycogen. It provides exogenous enzyme to reduce accumulation of glycogen in lysosomes.
Human recombinant tissue-nonspecific alkaline phosphatase (TNSALP) that hydrolyzes inorganic pyrophosphate (PPi), a natural inhibitor of hydroxyapatite crystal growth, thereby promoting bone mineralization.
5 mg/kg administered intravenously once every 2 weeks.
6 mg/kg administered subcutaneously once weekly.
None Documented
None Documented
Terminal half-life: 1.1–3.5 hours (mean 2.2 hours) after IV infusion; due to rapid uptake into lysosomes, shorter than many enzymes.
Terminal elimination half-life approximately 5.1 days (123 hours) in adults; supports once-weekly subcutaneous dosing for sustained pharmacodynamic effect.
Eliminated via reticuloendothelial system; no significant renal or biliary excretion. <5% recovered unchanged in urine.
Renal (primarily via proteolytic catabolism into small peptides and amino acids); negligible biliary or fecal elimination.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy